Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study | Synapse
September 16, 2024
Supplementary Figure S2 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary Figure S2 shows the duration of treatment including response and tumor type (the safety analysis set)
Preguntar a la IA
Me gusta
Guardar
Compartir
Preguntar a la IA
Me gusta
Guardar
Compartir
Cite This Study
Meric‐Bernstam et al. (Mon,) studied this question.